Title of Invention

A COMPOSITION FOR A CAPSULE COATING

Abstract highly suppress the decrease in gelatin-coating solubility over time, and particularly, can also impart a sufficient capsular strength when is applied to a soft capsule, and also provides a capsule coating and a capsule using the same. The composition for capsule coating is characterized by containing a gelatin (A) and an inositol phosphate (B) represented by a general formula: C6O6H12-n (H2PO3)n (wherein n represents an integer from 1 to 6).
Full Text DESCRIPTION
TECHNICAL FIELD
[0001]
The present invention relates to a composition for capsule coating containing a
gelatin, a capsule coating, and a capsule using the same.
The present invention claims priority on Japanese Patent Application No.
2004-223745 filed on July 30,2004, and Japanese Patent Application No. 2005-129968
filed on April 27, 2005, the content of which is incorporated herein by reference.
BACKGROUND ART
[0002]
In the field of food and drugs, gelatin capsules using gelatin for the coating
thereof are usually used in terms of safety, rapid solubility inside the body, and the like.
However, cross-linking caused by interaction between a gelatin molecule and at least one
of filled contents and decomposed matter thereof tends to cause a decrease in the coating
solubility of gelatin capsules, which influences the bioavailability of active ingredients.
This problem significantly occurs when the filled contents include galenicals, higher
unsaturated fatty acids such as DHA, EPA, or the like, unsaturated fatty acid
residue-containing oils and fats, minerals, mineral-containing yeasts, vitamin C, and the
like, in particular.
In order to solve the above-mentioned problem, (1) the addition of amino acids,
citric acids, tartaric acids, or fumaric acids to gelatin coating (Patent Document 1 and
Patent Document 2), (2) the addition of pullulan and polypeptide to gelatin coating
(Patent Document 3), and the like have been proposed.
[0003]
Moreover, it is known as a general problem of a soft capsule that the adhesion
thickness of a coating joined portion cannot be sufficiently obtained when the capsule is
formed, and so the strength of the capsule becomes insufficient. Therefore, leakage of
the contents of the capsule, rupture of the capsule, or the like is caused.
[Patent Document 1] Japanese Examined Patent Application, Second Publication No.
Sho 57-30088
[Patent Document 2] Japanese Unexamined Patent Application, First Publication No.
Sho 59-39834
[Patent Document 3] Japanese Unexamined Patent Application, First Publication No.
Hei 05-65222
DISCLOSURE OF THE INVENTION
[Problems to be Solved by the Invention]
[0004]
However, the above-mentioned prior arts (1) and (2) have not yet resulted in
sufficient prevention of the decrease in the coating solubility.
Also, the effects of the improvement in the strength of the soft capsule are not
necessarily sufficient.
The present invention has been achieved in view of the above-mentioned
circumstances, and has as an object thereof to provide a composition for a capsule
coating which can highly suppress the decrease in the coating solubility over time, and
can particularly give a sufficient capsular strength in the case of a soft capsule, and
provide a capsule coating and a capsule using the same.
[Means for Solving the Problems]
[0005]
The inventors of the present invention found that the above-mentioned problem
can be solved by formulating an inositol phosphate into a capsule coating, and thus
arrived at the present invention.
[0006]
That is, a composition for capsule coating according to the
characterized by containing a gelatin (A) and an inositol phosphate (B) represented by the
general formula: C6O6H12-n,(H2PO4)n (in the formula, n represents an integer from 1 to 6).
A capsule coating according to the present invention is characterized by
containing a gelatin (A) and an inositol phosphate (B) represented by the general
formula C5O6H12-n (H2PO3)„ (in the formula, n represents an integer from 1 to 6). In the
capsule coating according to the present invention, it is preferable that the component (B)
contain an inositol hexaphosphate.
[0007]
A capsule according to the present invention is characterized by including the
capsule coating according to the present invention. The capsule according to the present
invention is particularly effective when a filled content thereof contains at least one
selected from the group consisting of galenicals, unsaturated fatty acids, unsaturated fatty
acid residue-containing oils and fats, minerals, mineral-containing yeasts, and vitamin C.
Also, it is preferable that the capsule according to the present invention has a filled
content containing at least one selected from the group consisting of phospholipids,
amino sugars, and organic acids. Moreover, the capsule according to the present
invention is particularly effective in the case of a soft capsule.
10008]
The capsule according to the present invention may be a soft capsule.
A production method of the soft capsule is characterized by including a
production step of the composition for capsule coating containing at least a gelatin (A)
and an inositol phosphate (B) represented by the general formula:C6O6H12-n,(H2PO3)n(in
the formula, n represents an integer from 1 to 6), and an encapsulation step in which the
capsule coating is produced from the composition for capsule coating and a content to be
filled in the capsule is interposed between the capsule coating followed by conducting
pressure bonding.
Also, the above-mentioned production method may further include a step of
preparing the content to be filled containing at least one selected from the group
consisting of phospholipids, amino sugars, and organic acids,
[Effects of the Invention]
[0009]
According to the present invention, a composition for capsule coating which
can highly suppress the decrease in gelatin-coating solubility over time, and can
particularly impart a sufficient capsular strength in the case of a soft capsule, as well as a
capsule coating and a capsule using the same can be provided.
BEST MODE FOR CARRYING OUT THE INVENTION
[0010]
In the following, the present invention will be explained in detail.
"Composition for capsule coating and capsule coating"
The composition for the capsule coating according to the present invention is a
composition used for producing a capsule coating, and is characterized by containing at
least a gelatin (A) and an inositol phosphate (B) represented by the general formula:
C6O6H12-n(H2PO3)n (in the formula, n represents an integer from 1 to 6).
The capsule coating according to the present invention is characterized by
containing the gelatin (A) and the inositol phosphate (B) represented by the general
formula:C6O6H12-n(H2PO3)n (in the formula, n represents an integer from 1 to 6).
The inventors of the present invention found that addition of the inositol
phosphate to the gelatin coating significantly prevents the decrease incoating solubility
over time, that is, the decrease caused by, for example, cross-linking generated by
interaction between a gelatin molecule and filled contents or decomposed matter thereof,
and, in the case of a soft capsule, the addition causes joined portions of coating to be
bonded with a sufficient thickness. Therefore, the addition can impart a sufficient
capsular strength and prevent leakage of the content from the joined portions of the
coating, the rupture of the capsule, or the like.
[0011]
The gelatin (A), which is a main component, is not particularly limited, and
well-known gelatins used for general capsules, such as acid-treated gelatins, alkali-treated
gelatins, amphoterically-treated gelatins, chemically-modified gelatins, or the like may be
used. These may be used alone or in combination with two or more kinds thereof.
The gelatin is extracted after hydrolyzing a collagen, and, as a hydrolytic agent,
the "acid-treated gelatin" uses an acid such as hydrochloric acid, sulfuric acid, or the like,
the "alkali-treated gelatin" uses alkalis such as lime or the like, and the
"amphoterically-treated gelatin" uses both the acid and the alkali. Moreover, the
"chemically-modified gelatin" is one obtained by reacting an amino group of the gelatin
with an orgamc acid such as succinic acid, phthalic acid, or the like. Among them, the
acid-treated gelatin and the alkali-treated gelatin are preferably used.
[0012]
The inositol phosphate (B) is one represented by the above-formula, and
examples thereof include inositol monophosphate, inositol diphosphate, inositol
triphosphate, inositol tetraphosphate, inositol pentaphosphate, and inositol hexaphosphate
(phytic acid), each of which has 1 to 6 phosphate groups inserted therein (n=l to 6).
These may be used alone or in combination with two or more kinds thereof.
Among them, it is preferable to use as the component (B) inositol phosphates
having 3 to 6 phosphate groups (n=3 to 6), and particularly phytic acid having 6
phosphate groups (n=6); because effects of preventing the decrease in the solubility and
increasing strength are excellently exhibited.
[0013]
The amount of the inositol phosphate (B) added is not particularly limited.
However, when the amount of the component (B) is extremely low, effects obtained by
adding the component (effects of preventing the decrease in solubility and increasing the
strength) may not be sufficiently exhibited. On the other hand, when the amount is
extremely high, particularly in the case of the soft capsule, the decrease in capsular
strength or adhesion between capsules may be caused by decreasing the pH of the coating
or relatively decreasing the amount of gelatin. Accordingly, it is preferable that the
amount of the inositol phosphate (B) contained in the capsule coating be 0.05 to 15% by
mass, more preferably 1 to 10% by mass, and even more preferably 2 to 8% by mass,
with respect to the amount of the gelatin (A).
[0014]
In addition to the component (A) and the component (B), various additives
generally used for capsule coatings, such as, for example, plasticizers such as glycerin or
sorbitol for components other than the component (B), such as amino acids, citric acids,
or the like, antiseptics, coloring agents such as dyes or titanium oxide, organic acids, or
the like may be contained in the composition for capsule coating and the capsule coating
according to the present invention, as needed.
[0015]
The composition for capsule coating can be produced by mixing and dissolving
the components (A) and (B), and further various additives, as needed, in water at room
temperature or while heating.
[0016]
In brief explanation, the capsule coating can be produced by making the
composition for capsule coating into a film, forming the film into a predetermined shape,
and then drying. Although the content of water contained in the capsule coating after
drying is not particularly limited, 5 to 20% by mass, particularly 7 to 15% by mass is
preferable.
The time for forming the capsule coating and filling the content thereof is
determined depending on the type of the capsule. Although the present invention is
applicable for both soft capsules and hard capsules, the soft capsules are particularly
preferable.
The "soft capsule" is produced by formulating a plasticizer such as glycerin,
sorbitol, or the like, encapsulating a content to be filled by a film-like capsule coating
which is relatively soft with increased plasticity, and forming it into a predetermined
shape at the same time as or after encapsulating the content (encapsulation forming).
The "hard capsule" is produced by directly filling a content to be filled into a capsule
coating which is manufactured into a predetermined shape with relative hardness in
advance, or by slightly conducting shape forming after filling the content.
[0017]
The present invention is particularly effective in the case of the soft capsule
which relatively tends to generate cross-linking caused by interaction between a gelatin
molecule and the filled content or decomposed matter thereof.
In the case of the soft capsule, the capsule can be produced by, for example,
processing the composition for capsule coating into a film using a rotatory type soft
capsule filler, supplying the film into a roll-metal mold from both left and right sides
thereof, inserting while pressing a content to be filled into it just before punching it out
into a predetermined shape, conducting shape forming, and drying.
In i:he case of the hard capsule, an immersion method in which a stainless-steel
mold-pin is immersed in an immersion fluid prepared by dissolving a gelatin in purified
water while stirring and adding inositol phophate to the solution, and the mold-pin is
rotated in order to be dried can be used, for example.
[0018]
This composition for capsule coating and the capsule coating according to the
present invention can significantly prevent the decrease in the solubility of the gelatin
coating over time by formulating inositol phosphate (B), and, particularly, when the
capsule coating is applied to a soft capsule, a sufficient strength can be further given by
increasing the thickness of the joined portion of the capsule coating.
The technology of the present invention enables the use of conventional
methods without a change in the production of a capsule except that inositol phosphate
(B) is added to a conventional coating composition, and therefore, is preferable.
[0019]
"Capsule"
A capsule according to the present invention is characterized by including the
above-mentioned capsule coating of the present invention. Although the capsule may
be either a soft capsule or a hard capsule as described above , the soft capsule is
particularly preferable.
The form of the filled content is not particularly limited, and it may be a liquid,
suspension, paste, powder, granular, or the like. In the case of the granular, coating may
be formed using a coating agent.
[0020]
The capsule of the present invention can be used for various applications such
as pharmaceuticals, quasi-drugs, health foods, general foods, cosmetics, or the like, and
the constitution of the filled content is arbitrarily determined depending on the
application of the capsule.
In ihe present invention, formulation of inositol phosphate (B) into the capsule
coating can significantly inhibit the decrease in the coating solubility over time, and,
particularly, when the capsule coating is applied to a soft capsule, the thickness of the
joined portion of the capsule coating can be increased, so a sufficient strength can be
further given and effects can be exhibited in spite of the constitution of the filled content.
Moreover, the inventors of the present invention have found that when at least
one selected from the group consisting of phospholipids, amino sugars, and organic acids
is added to the tilled content, effects exhibited by the filled content on the capsule coating
decrease, so Ihe coating solubility can be further prevented from decreasing over time.
[0021]
The "phospholipid" is not particularly limited, and examples thereof include
phosphatidyl serine, phosphatidylcholine (lecithin), phosphatidylinositol,
phosphatidylethanolamine (cephalin), phosphatidylcardiolipin, phosphatidic acid,
sphingomyelin, derivatives thereof, and the like. These may be used alone or in
combination with two or more kinds thereof.
Among them, phosphatidylethanolamine and derivatives thereof are preferable
in view of their excellent effects of preventing the decrease in solubility. Examples of
the derivatives of phosphatidylethanolamine include a monoacyl type (lyzo type), alkenyl
type, N-methyl type and N, N-dimethyl type in which base portions are methylated,
N-acyl type, rand the like, of a phosphatidylethanolamine that is a diacyl type.
As phospholipid-containing products containing at least one of the
above-mentioned phospholipids, soybean phospholipid (soybean lecithin), yolk
phospholipid (yolk lecithin), and the like are commercially available, and these are easily
obtained and exhibit excellent effects, and so are preferably used. These may be
purified products or crudely purified products, and also may be hydrogenated products or
powdered products.
[0022]
The "amino sugar" is not particularly limited, and saccharides containing an
amino group such as glucosamine, N-acetyl glucosamine, galactosamine, N-acetyl
galactosamine, N-acetyl neuraminic acid, and the like, or polymers of glucosamine can
be used, for example. Specific examples thereof include compounds having a structure
in which a hydroxyl group of the saccharide is replaced with an amino group, such as
chitosan and the derivatives thereof, polygalactosamine and derivatives thereof.
Examples of chitosan and the derivatives thereof include low-molecular-weight chitosan,
high-molecular-weight chitosan, chitosan oligosaccharide, and the like, and all those
obtained by deacetylating chitins are preferably used. The amino sugars may be used
alone or in combination with two or more kinds thereof.
[0023]
The "organic acid" is not particularly limited, and examples thereof include
amino acids such as tryptophan, aspartic acid, glutamic acid, glycine, phenylalanine,
arginine, lysine, and the like, citric acid, succinic acid, fumaric acid, tartaric acid, lactic
acid, malic acid, inositol phosphate, and the like. These may be used alone or in
combination with two or more kinds thereof.
Among them, inositol phosphate and citric acid are preferable in view of their
excellent inhibitory effects against the decrease in the solubility. As inositol phosphate,
although the above-mentioned ones may be used, phytic acid is preferably used, in
particular.
[0024]
As described above, the filled content may contain at least one selected from
the group consisting of phospholipids, amino sugars, and organic acids, and the case in
which phospholipids and organic acids are contained is particularly preferable.
Although the amount of these added is not particularly limited, an extremely small
addition cannot demonstrate sufficient effects due to the addition, while an extremely
large addition relatively decreases the amount of an active ingredient of pharmaceuticals
or the like. Accordingly, it is preferable that the total amount of an addition with respect
to the total amount of the filled content be 0.05 to 20% by mass, more preferably 0.1 to
10% by mass, and even more preferably 0.5 to 10% by mass.
[0025]
Although the present invention can exhibit effects in spite of the constitution of
the filled content, it is particularly effective when the filled content contains at least one
selected from the group consisting of galenicals, unsaturated fatty acids, unsaturated fatty
acid residue-containing oils and fats, minerals, mineral-containing yeasts, and vitamin C,
because these significantly decrease the solubility of gelatin coating in the prior art.
[0026]
The term "galenicals" refers to those used in raw materials for pharmaceuticals
(including Qiinese medicinal drugs and folk medicines), perfumery, or spices, without
modification or after being simply processed or prepared by, for example, cutting,
crushing, and drying a part or all of an animal, a plant, or a mineral without changing the
nature thereof. In the capsule, the galenicals may be used in the form of powder,
extract, essence, tincture, or the like.
[0027]
Specific examples of galenicals include plants such as Mallotus bark, Gambir,
Aloe, Epimedium herb, Fennel, Mume fruit, Lindera root, Bearberry leaf, Turmeric, Rose
fruit, Acanthopanacis cortex, Corydails tuber, Rabdosiae herb, Milkvetch root, Scutellaria
root, Solomonseal rhizome, Phellodendron bark, Japanese cherry bark, Coptis rhizome,
Polygala root, Phocae testis et penis, SEA horse, Polygonum tuber, Zedoary, Puerariae
radix, ValeriEinae radix, Guarana, Glycyrrhiza, Platycodon root, Immature orange,
Apricot kernel, Barbary wolfberry fruit, Schizonepeta spike, Cinnamon bark, Cassia seed,
Gentian, Geranium herb, Red ginseng, Magnolia bark, Oriental bezoar, Acanthopanacis
cortex, Achyranthes root, Evodia fruit, Schisandra fruit, Bupleurum root, Asiasari root,
Thyme, Sage, Smilax rhizome, Hawthorn fruit, Gardenia fruit, Cornus fruit, Zanthoxylum
fruit, Zizyphus seed, Dioscorea rhizome, Rehmannia root, Civet, Peony root, Cnidium
fruit, Plantago herb, Houttuynia herb, Amomum seed, ginger, Cardamon, Glossy privet
fruit, Earthworm, Magnoliae flos, Senega, Cnidium rhizome, Peucedani radix, Swertia
herb, Atractylodis lance ae rhizoma, Mori cortex, Perillae herba, Rhubarb, Zizyphi
fructus, Clove, Gambir plant, Citrus unshiu peel, Capsicum, Japanese angelicae root,
Tangshen, Peach kernel, Bitter orange peel, Ipecac, Dodder seed, Eucommia bark,
Nandinae fructus, Nanbange, Cistanchis herb, garlic, Ophiopogonis tuber, Glehnia root,
Pinellia tube)-, Agkistrodon japonicae, Atractylodis rhizoma, Poria sclerotium,
Sinomenium stem, Malaytea scurfpea fruit, Moutan cortex, Hop, Ephedra herb,
Actinidiae fructi galla, Muira puama, Saussureae radix, Coicis semen, Longan arillus,
Gentianae scabrae radix, Scopolia rhizome, Cervi parvum cornu, Chrysanthemum flower,
Oat leaflet, Safflower, Salacia, Honeysuckle stem, Ginseng (such as Panaxginseng,
Panaxnotoginseng, or the like), Artemisia, green tea, herbs (such as ginkgo biloba, St
John's wort, chamomile, Piper methysticum, blueberry, bilberry, Serenoa repens, Salacia
oblonga, garcinia cambogia, rosemary, citrus, Vinca minor, echinacea, and the like), and
the like, extracts, essences, or tinctures thereof;
powders obtained by drying and pulverizing without modification fungus (fruit
body) such as Agaricus, Phellinus linteus, Ganoderma lucidum, Flammulina veluptipes,
Schizophyllum commune, shiitake mushroom, Grifola frondosa, Chaga (Fuscoporia
obliqua), mushroom, Lyophyllum decastes, Coriolus versicolor, Crepidotus mollis,
bracket fungus, Cordyceps sinensis saccardo, Ganoderma lucidum, or the like, essences
extracted from the fungus using hot water (which may include ethanol), essence powders,
and the like;
extracts of animals, hydrolysates obtained by treating the extracts using acids,
bases, or enzymes, those collected from the nests of animals (such as, for example, ox
bile, chondroitin, glucosamine, collagen, propolis, and the like);
essences of fermented substances obtained by fermenting cereals, plants,
marine products, or the like, using koji molds, red koji molds, lactic acid bacterias, acetic
acid bacterias, bacillus natto, yeasts, or the like;
Chinese medicinal drugs composed of a combination of galenicals such as, for
example, Kakkonto (Puerariae radix, Zizyphi fructus, Peony root, ginger, Ephedra herb,
Cinnamon bark, Glycyrrhiza), Tokishokuyakusan (Japanese angelicae root, Notopterygii
rhizome, Peony root, Poria sclerotium, Atractylodis lanceae rhizoma, Alismatis rhizoma),
Hachimijio (Rehmannia root, Dioscorea rhizome, Poria sclerotium, Cinnamon bark,
Cornus fruit, Alismatis rhizoma, Moutan cortex, Aconiti ruber), Shoseiryuto (Ephedra
herb, ginger, Cinnamon bark, Schisandra fruit, Peony root, Glycyrrhiza, Asiasari root,
Pinellia tuber), Bakumondoutou (Ophiopogonis tuber, Oryzae fructus, Ginseng, Pinellia
tuber, Zizyplu fructus, Glycyrrhiza), Kami-shoyosan (Japanese angelicae root,
Atractylodis lanceae rhizoma, Bupleurum root, Gardenia fruit, ginger, Peony root, Poria
sclerotium, Moutan cortex, Glycyrrhiza, Mentha herb), and the like.
The filled content may include at least one of these galenicals.
The present invention is particularly effective when the filled content includes
rosemary, citrus, blueberry, bilberry, propolis, Panaxnotoginseng, Panaxginseng,
Agaricus, Phellinus linteus, shiitake mushroom, Ganoderma lucidum, and essences
thereof, because the effect of preventing the decrease in coating solubility is significant.
[0028]
Although the "unsaturated fatty acid" is not particularly limited, the present
invention is particularly effective when the filled content contains a long-chain
unsaturated fatty acid having at least 14 carbon atoms, and more preferably 14 to 22
carbon atoms, because the effect of preventing the decrease in coating solubility is
significant.
Examples of the long-chain unsaturated fatty acid having at least 14 carbon
atoms include DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), linoleic acid,
arachidonic acid, oleic acid, pinolenic acid, sciadonic acid, Jinoiperon acid, columbinic
acid, conjugated linoleic acid, eleostearic acid, octadecenoic acid, octadecadienoic acid,
docosenoic acid, ricinoleic acid, a-linolenic acid, y-linolenic acid, behenic acid, and the
like. The filled content may contain at least one of these unsaturated fatty acids. The
present invention is particularly effective when the filled content contains DHA and/or
EPA.
The unsaturated fatty acid may be formulated in the form of an isolated product
of the unsaturated fatty acid or oil containing the same.
[0029]
The phrase "unsaturated fatty acid residue-containing oils and fats" refers to
oils and fats in which at least one of fatty acid residues composing the oils and fats is an
unsaturated fatty acid residue.
Examples of the oils containing at least one of the unsaturated fatty acid
residue-containing oils and fats include vegetable oils such as soybean oil, rape seed oil,
rice bran oil, cotton seed oil, sesame oil, sunflower oil, mustard oil, safflower oil, corn
oil, peanut oil, olive oil, palm oil, coconut oil, and the like, and animal oils such as fish
oil, whale oil, beef tallow, lard, milk fat, and the like. The filled content may contain at
least one of these oils.
The present invention is particularly effective when the filled content contains a
fish oil, because many unsaturated fatty acids (DHA and EPA) described above are also
contained in the unsaturated fatty acid residue-containing oils and fats, and the effect of
preventing the decrease in coating solubility is significant.
[0030]
The "mineral" is not particularly limited, and it refers to an inorganic substance
that is useful from a nutritional standpoint. Examples thereof include calcium,
phosphorus, iron, sodium, potassium, magnesium, zinc, selenium, copper, and the like.
Among them, the present invention is particularly effective when calcium, phosphorus,
iron, magnesium, zinc, selenium, or copper is contained, because use of polyvalent
elements as a. content filled in a conventional capsule significantly causes the
insolubilization of the coating thereof, but the insolubilization can be inhibited in the
capsule of the present invention. These may be used as inorganic or organic salts used
for common foods.
[0031]
The "mineral-containing yeast" is not particularly limited, and examples thereof
include magnesium-containing yeasts, zinc-containing yeasts, selenium-containing
yeasts, iron-containing yeasts, copper-containing yeasts, and the like. The
mineral-containing yeast is one in which a mineral is incorporated in the yeast body.
[0032]
The filled content may arbitrarily contain, in addition to the above-mentioned
components, additives generally used for pharmaceuticals, food, or the like, such as
excipients, bonding agents, disintegrators, stabilizers, dispersants, coloring agents,
flavoring compounds, medium-chain fatty acid monoglycerides, medium-chain fatty acid
triglycerides, polyethylene glycols, surfactants (glycerin fatty acid esters, or the like),
antioxidants (vitamin E, astaxanthin, catechin, or the like), or the like, as needed.
[0033]
Since the capsule of the present invention includes the capsule coating of the
present invention, the decrease in solubility over time is significantly prevented, and
particularly in the case of a soft capsule, a sufficient strength is given to the capsule.
Paiticularly, formulation of at least one selected from the group consisting of
phospholipids, amino sugars, and organic acids in the filled content can further prevent
the decrease in solubility, and is preferable.
[Examples]
[0034]
In ihe following, although test examples with respect to the present invention
will be mentioned, the present invention is not limited to these.
Effect of Inhibiting Decrease in Coating Solubility
"Test Example 1" (Examples 1-1, 1-2 and Comparative Examples 1-1 to 1-3)
(Preparation of Gelatin Coating)
100 g of gelatin and 45 g of glycerin were added to 100 g of purified water to
make them absorb water and swell, followed by dissolving them at approximately 80°C
to prepare a gelatin solution. To this solution, each organic acid of which the kind and
content are indicated in Table 1 (the concentration shown in the table represents the
concentration (% by mass) with respect to the total amount of composition) was added,
mixed, and then deaerated under reduced pressure to prepare a composition for capsule
coating.
Each obtained composition was poured into a TLC plate, uniformly spread to a
thickness of 1 mm, and then dried at 30°C for 24 hours to obtain a film-like gelatin
coating having a moisture content of approximately 9%. The coating obtained in each
example was cut into a 1 cm x 1 cm piece, and used for the following evaluation.
[0035]
(Evaluation)
15 ml of DHA (fish oil) was poured in a screw tube, into which two pieces of
each gelatin coating piece prepared in the respective example were immersed, and stored
at 50°C. After one or two day(s), the gelatin coating pieces were taken out, and the
content adhered to the pieces was removed, followed by putting the pieces in 200 ml of
hot water at 60°C and stirring them with a stirrer bar for 2 minutes. The pieces were
visually observed in the state of repose, and evaluated in accordance with the following
criteria.
Criteria for Evaluation
(-): The gelatin coating pieces were completely dissolved, and undissolved
pieces thereof were not recognized.
(i): Undissolved pieces were slightly recognized.
(+): Undissolved pieces were recognized in small amounts.
(-H-): Undissolved pieces were recognized in medium amounts.
(-+-+): Undissolved pieces were recognized in large amounts.
(+-+-+-): The gelatin coating pieces were not dissolved at all, and completely
insolubilized.
[0036]
(Results)
Results are shown in Table 1.
In Comparative Examples 1-1 to 1-3, the gelatin coating was completely
insolubilized after two days, while in Examples 1-1 and 1-2 in which inositol
hexaphosphate (phytic acid) was added, the gelatin coating was completely dissolved
even after two days. Accordingly, it was apparent that addition of inositol
hexaphosphate significantly prevented the decrease in solubility of the gelatin coating
over time.
[0037]

[0038]
"Test Example 2" (Examples 2-1 to 2-13)
(Preparation of Soft Capsule)
Each composition for the capsule coating composed of 45% by mass of gelatin,
18% by mass of glycerin, inositol phosphate of the kind in an amount as indicated in
Table 2 (the concentration shown in the table represents the concentration (% by mass)
with respect to the total amount of respective composition), and water (the remnant) was
produced in the same way as that of Test Example 1, followed by deaerating and being
kept for 10 hours to use for producing capsules.
Each component of which the kind and content are indicated in the same table
was filled using a rotatory type soft capsule filler (Oval Type 5). After filling, each
capsule coating was dried at 27°C under 50% or lower humidity till the moisture content
in the capsule coating became 8% and so a soft capsule was prepared.
[0039]

Effect of Giving Strength to Capsule
"Test Example 3" (Example 3 and Comparative Example 3)
(Preparation of Gelatin Coating and Soft Capsule)
A gelatin solution (A) composed of 45% by mass of gelatin, 18% by mass of
glycerin, 1% by mass of inositol hexaphosphate (phytic acid), and 36% by mass of water,
and a gelatin solution (B) composed of 45% by mass of gelatin, 18% by mass of glycerin,
and 37% by mass of water were each prepared, dissolved at 80°C, deaerated, and then
kept for about 10 hours. Each gelatin coating with a thickness of 0.90 mm was formed
from the gelatin solution (A) or (B) using a rotatory type soft capsule filler (Oval Type
5), into which 300 mg of DHA (fish oil) was filled to prepare soft capsules. The
capsules were evaluated as described below.
[0041]
(Evaluation)
Immediately after starting to fill each, filled capsules No. 1, No. 4, and No. 7
(front, middle, back) were sampled from capsule filler metal molds No. 1 to No. 7, and
each content thereof was removed therefrom, followed by cutting in round slices to
measure the thickness of the thinnest portion of the joined portion thereof using a
microscope with a scale for comparison. Moreover, after operating the filler for 1 hour
using the respective gelatin solution, filled capsules were sampled in the same way as
described above, and the thickness of the thinnest portion of the joined portion thereof
was measured for evaluation. Next, the adhesion ratio was calculated from the
thickness of the joined portion for evaluation.
[0042]
(Results)
Results are shown in Table 3 and Table 4.
In comparison with Comparative Example 3 in which the capsules were
produced using the gelatin solution (B), Example 3 in which the capsules were produced
using the gelatin solution (A) containing inositol hexaphosphate (phytic acid)
demonstrated a high adhesion ratio and it was confirmed that the strength of the capsules
increased.
[0043]
We Claim:
1. A composition for a capsule coating characterized by comprising a gelatin (A) and an
inositol phosphate (B) represented by a general formula: C6O6H12-n(H2PO3)n (wherein n
represents an integer from 1 to 6),
wherein the amount of the inositol phosphate (B) is 0.05 to 15% by mass.
2. A capsule coating characterized by comprising a gelatin (A) and an inositol phosphate
(B) represented by a general formula: C6O6H12-n(H2PO3)n (wherein n represents an integer from
1 to 6).
3. A capsule coating as claimed in claim 2, wherein the component (B) comprises an
inositol hexaphosphate.
4. A capsule comprising the capsule coating as claimed in claim 2 or 3.
5. A capsule as claimed in claim 4, wherein a filled content thereof comprises at least one
selected from the group consisting of galenicals, unsaturated fatty acids, unsaturated fatty acid
residue-containing oils and fats, minerals, mineral-containing yeasts, and a vitamin C.
6. A capsule as claimed in claim 4 or 5, wherein a filled content thereof comprises at least
one selected from the group consisting of phospholipids, amino sugars, and organic acids.
7. A capsule as claimed in any one of claims 4 to 6, being a soft capsule.
8. A production method of the capsule as claimed in claim 7, comprising a production step
of a composition for a capsule coating containing at least a gelatin (A) and an inositol phosphate
(B) represented by a general formula: C6O6H12-n(H2PO3)n (wherein n represents an integer from
1 to 6) and an encapsulation step in which the capsule coating is produced from the composition
for the capsule coating and a content to be filled in the capsule is interposed between the capsule
coating followed by a pressure bonding.
9. A production method as claimed in claim 8, comprising a step of preparing the content to
be filled containing at least one selected from the group consisting of phospholipids, amino
sugars, and organic acids.


highly suppress the decrease in gelatin-coating solubility over time, and particularly, can
also impart a sufficient capsular strength when is applied to a soft capsule, and also
provides a capsule coating and a capsule using the same. The composition for capsule
coating is characterized by containing a gelatin (A) and an inositol phosphate (B)
represented by a general formula: C6O6H12-n (H2PO3)n (wherein n represents an integer
from 1 to 6).

Documents:

00304-kolnp-2007-assignment.pdf

00304-kolnp-2007-correspondence.pdf

00304-kolnp-2007-g.p.a.pdf

0304-kolnp-2007-abstract.pdf

0304-kolnp-2007-claims.pdf

0304-kolnp-2007-correspondence others.pdf

0304-kolnp-2007-description(complete).pdf

0304-kolnp-2007-form-1.pdf

0304-kolnp-2007-form-3.pdf

0304-kolnp-2007-form-5.pdf

0304-kolnp-2007-international publication.pdf

0304-kolnp-2007-pct form.pdf

0304-kolnp-2007-priority document.pdf

304-KOLNP-2007-(13-02-2012)-CORRESPONDENCE.pdf

304-KOLNP-2007-ABSTRACT.pdf

304-KOLNP-2007-AMANDED CLAIMS-1.1.pdf

304-KOLNP-2007-AMANDED CLAIMS.pdf

304-kolnp-2007-amanded pages of specification.pdf

304-KOLNP-2007-ASSIGNMENT 1..pdf

304-KOLNP-2007-ASSIGNMENT.pdf

304-KOLNP-2007-CORRESPONDENCE 1..pdf

304-KOLNP-2007-CORRESPONDENCE 1.1.pdf

304-KOLNP-2007-CORRESPONDENCE 1.2.pdf

304-KOLNP-2007-CORRESPONDENCE 1.3.pdf

304-KOLNP-2007-CORRESPONDENCE-1.4.pdf

304-KOLNP-2007-DESCRIPTION (COMPLETE).pdf

304-KOLNP-2007-ENGLISH TRANSLATION.pdf

304-KOLNP-2007-EXAMINATION REPORT REPLY RECIEVED.pdf

304-KOLNP-2007-EXAMINATION REPORT.pdf

304-KOLNP-2007-FORM 1.pdf

304-KOLNP-2007-FORM 13 1...pdf

304-KOLNP-2007-FORM 13-1.1.pdf

304-KOLNP-2007-FORM 13.pdf

304-kolnp-2007-form 18.pdf

304-KOLNP-2007-FORM 2.pdf

304-KOLNP-2007-FORM 3 1.1.pdf

304-KOLNP-2007-FORM 3.pdf

304-KOLNP-2007-FORM 5.pdf

304-KOLNP-2007-GPA.pdf

304-KOLNP-2007-GRANTED-ABSTRACT.pdf

304-KOLNP-2007-GRANTED-CLAIMS.pdf

304-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf

304-KOLNP-2007-GRANTED-FORM 1.pdf

304-KOLNP-2007-GRANTED-FORM 2.pdf

304-KOLNP-2007-GRANTED-SPECIFICATION.pdf

304-kolnp-2007-marked copy.pdf

304-KOLNP-2007-OTHERS-1.1.pdf

304-KOLNP-2007-OTHERS.pdf

304-KOLNP-2007-PA.pdf

304-KOLNP-2007-PETITION UNDER RULE 137.pdf

304-KOLNP-2007-REPLY TO EXAMINATION REPORT 1.1.pdf


Patent Number 251140
Indian Patent Application Number 304/KOLNP/2007
PG Journal Number 09/2012
Publication Date 02-Mar-2012
Grant Date 27-Feb-2012
Date of Filing 25-Jan-2007
Name of Patentee WAKUNAGA PHARMACEUTICAL CO., LTD.
Applicant Address 5-36, MIYAHARA 4-CHOME, YODOGAWA-KU, OSAKA-SHI, OSAKA
Inventors:
# Inventor's Name Inventor's Address
1 SHIMOKAWA, YOSHIYUKI C/O WAKUNAGA PHARMACEUTICAL CO., LTD., 1624, SHIMOKOTACHI, KODA-CHO, AKITAKATA-SHI, HIROSHIMA-KEN
2 MIHARA, MIKA C/O WAKUNAGA PHARMACEUTICAL CO., LTD., 1624, SHIMOKOTACHI, KODA-CHO, AKITAKATA-SHI, HIROSHIMA-KEN.
3 SHIRAISHI, SUMIHIRO C/O WAKUNAGA PHARMACEUTICAL CO., LTD., 1624, SHIMOKOTACHI, KODA-CHO, AKITAKATA-SHI, HIROSHIMA-KEN
PCT International Classification Number A61K 9/64
PCT International Application Number PCT/JP2005/013916
PCT International Filing date 2005-07-29
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 2004-223745 2004-07-30 Japan
2 2005-129968 2005-04-27 Japan